Spots Global Cancer Trial Database for Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
Official Title: A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH
Study ID: NCT01092585
Conditions
Interventions
Study Description
Brief Summary: Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced melanoma and normal serum lactate dehydrogenase (LDH).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Agop Y Bedikian, MD
Affiliation: The University of Texas MD Anderson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
